| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Gibberellin A7 does not have a defined biological target in mammalian systems, as it is a plant hormone. In plants, gibberellins function by binding to a receptor protein within the plant cell. GA7 is a metabolite of Gibberella fujikuroi. While it lacks direct mammalian targets, it has been studied for its effects on NF-κB, anti-Candida, and antioxidant activities. In vitro, GA7 exhibits anti-Candida activity against Candida albicans and shows antibiofilm properties at 940 mM concentration. It also shows antioxidant activity against peroxyl radicals and can inhibit flower bud formation in some plants.
|
|---|---|
| ln Vitro |
In vitro, gibberellin A7 (188-940 μM) reduces the viability of C. albicans biofilm cells. It exhibits anti-Candida activity against Candida albicans. GA7 also shows antioxidant activity against peroxyl radicals. In plant cell studies, GA7 stimulates the growth of plant cells. It has been reported to exist in Fusarium fujikuroi, Ornithogalum thyrsoides, and several other organisms.
|
| ln Vivo |
Gibberellin A7 is not a pharmacologically active drug and does not exhibit in vivo biological activity in mammalian systems. It is primarily used as a plant growth regulator in agricultural and research settings. As a plant hormone, it promotes plant growth and development. It has been reported to inhibit flower bud formation in some plants. No in vivo pharmacological activity has been documented for this compound in animals.
|
| Enzyme Assay |
In vitro enzyme assays for gibberellin A7 are not standard, as it is a plant hormone rather than a biologically active test compound for mammalian targets. For anti-Candida activity, a standard protocol involves culturing C. albicans in appropriate media and treating with varying concentrations of GA7 (188-940 μM) to assess biofilm cell viability. For antioxidant activity, GA7 is tested against peroxyl radicals using standard radical scavenging assays. Quality control includes HPLC purity analysis (>98%).
|
| Cell Assay |
In vitro cell culture experiments with gibberellin A7 are not standard for mammalian cells, as it is a plant hormone. When studying its anti-Candida activity, fungal cells are cultured in appropriate media and treated with GA7 to assess biofilm formation and cell viability. For plant cell studies, GA7 is used to stimulate the growth of plant cells in culture. No mammalian cell-based assays are typically performed with this compound.
|
| Animal Protocol |
In vivo animal studies are not conducted with gibberellin A7, as it is a plant hormone and not a therapeutic test article. The compound is not used in pharmacological or toxicological studies in animals. Its applications are limited to plant physiology research and agricultural use as a growth regulator. No in vivo efficacy or safety studies have been reported for this compound in mammals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of gibberellin A7 are not characterized in mammalian systems, as it is not a drug substance. Based on its physicochemical properties (molecular weight 330.37, LogP 1.76, density 1.4±0.1 g/cm³), the compound would be expected to have moderate lipophilicity. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Gibberellin A7 has low toxicity for laboratory use. It is not classified as hazardous under normal handling conditions. The compound is not known to be mutagenic, carcinogenic, or reproductively toxic. Standard laboratory precautions (gloves, safety glasses) are recommended. GA7 is not intended for human or veterinary use and has not undergone rigorous toxicological evaluation for therapeutic applications.
|
| References | |
| Additional Infomation |
Gibberellin A7 is a C19-gibberellin, belonging to the pentacyclic diterpenoid class of compounds responsible for promoting plant growth and development. It was initially discovered in Gibberella fujikuroi, differing from gibberellin A1 in that it lacks a hydroxyl (OH) group at the C-7 position (gibberellin designation). It functions as a plant metabolite, bacterial metabolite, and mouse metabolite. It is a lactone, gibberellin monocarboxylic acid, and C19-gibberellin. Gibberellin A7 has been reported to exist in Fusarium fujikuroi, Ornithogalum thyrsoides, and several other organisms with relevant data.
Gibberellin A7 is a naturally occurring plant hormone initially discovered in Gibberella fujikuroi. It differs from gibberellin A1 in that it lacks a hydroxyl group at the C-7 position. GA7 functions as a plant metabolite, bacterial metabolite, and mouse metabolite. It is a lactone, gibberellin monocarboxylic acid, and C19-gibberellin. The compound has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C19H22O5
|
|---|---|
| Molecular Weight |
330.37
|
| Exact Mass |
330.146
|
| CAS # |
510-75-8
|
| PubChem CID |
92782
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
582.0±50.0 °C at 760 mmHg
|
| Flash Point |
214.6±23.6 °C
|
| Vapour Pressure |
0.0±3.7 mmHg at 25°C
|
| Index of Refraction |
1.636
|
| LogP |
1.76
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
24
|
| Complexity |
725
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O1C(C2(C([H])([H])[H])[C@]([H])(C([H])=C([H])[C@]31C2([H])C([H])(C(=O)O[H])[C@]12C([H])([H])C(=C([H])[H])[C@]([H])(C([H])([H])C([H])([H])C13[H])C2([H])[H])O[H])=O
|
| InChi Key |
SEEGHKWOBVVBTQ-NFMPGMCNSA-N
|
| InChi Code |
InChI=1S/C19H22O5/c1-9-7-18-8-10(9)3-4-11(18)19-6-5-12(20)17(2,16(23)24-19)14(19)13(18)15(21)22/h5-6,10-14,20H,1,3-4,7-8H2,2H3,(H,21,22)/t10-,11-,12+,13-,14-,17-,18+,19-/m1/s1
|
| Chemical Name |
(1R,2R,5R,8R,9S,10R,11S,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylic acid
|
| Synonyms |
GA7; Gibberellin A7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (756.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0269 mL | 15.1345 mL | 30.2691 mL | |
| 5 mM | 0.6054 mL | 3.0269 mL | 6.0538 mL | |
| 10 mM | 0.3027 mL | 1.5135 mL | 3.0269 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
